Abstracts tagged "Biomarkers"

Abstract Number: 381 • 2013 ACR/ARHP Annual Meeting
Coronary Endothelial Dysfunction Directly Measured By N13 Positron Emission Tomography (PET) Is Detected In Established Rheumatoid Arthritis (RA), But Not Early RA
OM Troum¹, OL Pimienta¹, B Hidalgo² and WA Hsueh³, ¹Keck School of Medicine, University of Southern California, Los Angeles, CA, ²Biostatistics, University of Alabama, Birmingham, AL, ³Medicine, Weill Cornell Medical College, Houston, TX
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular (CV) disease. The endothelium is a key regulator of vascular function. Subclinical CV disease and…
Abstract Number: 2374 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects
Jeffrey Voss¹, Candace Graff², Annette Schwartz³, Deborah Hyland⁴, Maria Argiriadi⁴, Heidi Camp⁵, Lori Dowding⁴, Michael Friedman⁴, Kristine Frank⁵, Jonathon George⁴, Eric Goedken⁴, Gloria Lo Schiavo⁴, Michael Morytko⁴, Robert o'Brien⁴, Robert Padley⁶, Matthew Rosebraugh⁵, Michael Rozema⁵, Kent Stewart⁵, Grier Wallace⁴, Neil Wishart⁴, Anwar Murtaza⁷ and Lisa Olson³, ¹Immunology, AbbVie Pharmaceuticals, Worcester, MA, ²Drug Metabolism and Pharmacokinetics, Abbvie Pharmaceuticals, worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Abbvie Pharmaceuticals, worcester, MA, ⁵abbvie pharmaceuticals, north chicago, IL, ⁶AbbVie, Inc, North Chicago, IL, ⁷Broad Institute, Cambridge, MA
Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there…
Abstract Number: 1878 • 2013 ACR/ARHP Annual Meeting
Proteomics Analysis Of Cartilage Secretome: A Powerful Tool For The Discovery Of OA Biomarkers
Lucía Lourido¹, Valentina Calamia¹, Patricia Fernández-Puente¹, Jesus Mateos¹, Beatriz Rocha², Carolina Fernández-Costa², Francisco J. Blanco¹ and Cristina Ruiz-Romero³, ¹Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ³Grupo de Proteomica-PBR2-ProteoRed/ISCIII Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006 A Coruña, Spain, A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is characterized by the progressive loss of cartilage structural extracellular matrix (ECM) components, mainly collagenous and non-collagenous proteins. The release of these…
Abstract Number: 1312 • 2013 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity Score Correlates With Radiographic Progression In Early Rheumatoid Arthritis: Results From a Randomized Trial
Karen Hambardzumyan¹, Rebecca Bolce², Scott E. Cruickshank³, Eric H. Sasso², David Chernoff², Kristina Forslind⁴, Saedis Saevarsdottir⁵, Ingemar F. Petersson⁶, Pierre Geborek⁷, Sofia Ernestam⁸ and Ronald F van Vollenhoven⁹, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Scott E. Cruickshank and Associates, Inc., Santa Barbara, CA, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Lund University, Lund, Sweden, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁸Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, ⁹ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), predictors of radiographic damage would be useful for optimal targeting of therapy. It has been suggested that combining various…
Abstract Number: 349 • 2013 ACR/ARHP Annual Meeting
Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis
Agnes Szentpetery¹, Mark Kilbane², Myra P. O'Keane², Muhammad Haroon³, Phil Gallagher⁴, Susan van der Kamp⁵, Malachi McMenna⁶ and Oliver FitzGerald³, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Metabolism Laboratory, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵DXA Unit, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁶Department of Endocrinology & Metabolic Bone Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: There is a growing interest in bone and cartilage biomarkers that could be used predicting and assessing changes in structural damage in inflammatory arthritis.…
Abstract Number: 2377 • 2013 ACR/ARHP Annual Meeting
Biomarkers Associated With Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate With Changes In Clinical Response In Subjects Treated With Mavrilimumab At Doses Above 10 Mg
Wendy White¹, Patricia Ryan², Xiang Guo³, Dominic Sinibaldi⁴, Gopi Ranganna⁵, Alex Godwood⁶, Didier Saurigny⁶, David Close⁶, Steve Eck⁴, Dee Wilkins¹, Lorin Roskos⁷, Matthew A. Sleeman⁸, Wanying Li⁹, Guy Cavet⁹ and Nadine A. Defranoux⁹, ¹Translational Sciences, MedImmune, Gaithersburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune LLC, Gaithersburg, MD, ⁴MedImmune, LLC, Gaithersburg, MD, ⁵Clinical Development, MedImmune, LLC, Cambridge, United Kingdom, ⁶MedImmune, Ltd, Cambridge, United Kingdom, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ⁹Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through effects on macrophages and neutrophils. Mavrilimumab (CAM-3001) is a human monoclonal…
Abstract Number: 1863 • 2013 ACR/ARHP Annual Meeting
SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity
Elena Gkrouzman¹, Mikhail Olferiev¹, Margaret Robotham¹, Mari Lliguicota¹, Wei-Ti Huang², Elzbieta E. Jacek¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) has been implicated in SLE pathogenesis, and cross-sectional studies have shown that IFN-I pathway activation is associated with multiple disease…
Abstract Number: 1283 • 2013 ACR/ARHP Annual Meeting
Power Doppler Ultrasound Phenotyping of Expanding Versus Collapsed Popliteal Lymph Nodes in Murine Inflammatory Arthritis
Echoe M. Bouta¹, Yawen Ju², Homaira Rahimi³, Ronald Wood⁴, Lianping Xing⁵ and Edward M. Schwarz⁶, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³Pediatrics, University of Rochester, Rochester, NY, ⁴Department of Urology, University of Rochester Medical Center, Rochester, NY, ⁵Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁶Center for Musculoskeletal Research, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis is a chronic inflammatory disease manifested by episodic flares in affected joints that are challenging to predict and treat. Longitudinal contrast…
Abstract Number: 307 • 2013 ACR/ARHP Annual Meeting
Abnormal Imaging and Increased Osteoclast Precursors In a Psoriasis Cohort Are Associated with New Onset of Psoriatic Arthritis
Ralf G. Thiele¹, Yahui Grace Chiu¹, Francisco A. Tausk², Bethany A. Marston¹, Gregory Dieudonne³, Vaseem Chengazi³, Michelle Smith¹, Sharon Moorehead¹, Rick Barrett¹ and Christopher T. Ritchlin¹, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Dermatology, University of Rochester, Rochester, NY, ³Radiology, University of Rochester, Rochester, NY
Background/Purpose: Psoriasis (Ps) precedes joint inflammation by about 10 years in patients who develop psoriatic arthritis (PsA). Several studies have documented abnormal musculoskeletal imaging findings…
Abstract Number: 70 • 2013 ACR/ARHP Annual Meeting
Chondrocyte Hypertrophy, Measured By The Secretion Of Collagen Type X, Is Associated With Cartilage Degradation and Systemic Inflammation In Osteoarthritis
Yi He¹, Natasja Stæhr Gudman², Niels Ulrik Hansen¹, Jianxia Wang³, Di Su⁴, Qinlong Zheng⁴, Ole Simonsen⁵, Kristian Kjaer Petersen⁶, Moustapha Kassem⁷, Morten Asser Karsdal² and Anne C. Bay-Jensen⁸, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Cartilage biology and biomarkers, Nordic Bioscience China, Beijing, China, ⁴Nordic Bioscience China, Beijing, China, ⁵Frederikshavn Hospital, Frederikshavn, Denmark, ⁶Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark, Center for Sensory-Motor Interaction, Aalborg, Denmark, ⁷Department of Endocrinology and Metabolism, Odense University Hospital and University of Southern, Odense, Denmark, ⁸Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) is the most common degenerative joint disease, of which the pathogenesis is inadequately understood. The hypertrophy-like changes, such as expression of hypertrophy…
Abstract Number: 2288 • 2013 ACR/ARHP Annual Meeting
Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients
Jason Ptacek¹, Rachael Hawtin², Brent Louie¹, Erik Evensen¹, James Cordeiro¹, Barbara Mittleman¹, Michelle Atallah¹, Alessandra Cesano², Clifton O. Bingham III³, Stacey Cofield⁴, Jeffrey R. Curtis⁵, Maria I. Danila⁴, Richard A. Furie⁶, MC Genovese⁷, Marc C. Levesque⁸, Larry W. Moreland⁸, Peter A. Nigrovic⁹, James R. O'Dell¹⁰, William H. Robinson¹¹, Nancy A. Shadick⁹, E. William St Clair¹², Christopher C. Striebich¹³, Geoffrey M Thiele¹⁴, Peter K. Gregersen⁶ and S. Louis Bridges Jr.⁴, ¹Nodality, Inc., South San Francisco, CA, ²Nodality Inc., South San Francisco, CA, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, School of Public Health, Birmingham, AL, ⁶The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁷Stanford University, Palo Alto, CA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Brigham and Women's Hospital/Harvard University, Cambridge, MA, ¹⁰Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ¹¹VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ¹²Medicine, Duke Unversity Medical Center, Durham, NC, ¹³University of Colorado Denver, Aurora, CO, ¹⁴Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Biomarkers reflecting immune function and associating with disease activity can help stratify rheumatoid arthritis (RA) patients (pts) in practice and in clinical trials.…
Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting
Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies
Edward Bernton¹, Antonio Polley², Susan Zondlo², Lynne Mitchell³ and Dennis Hourcade³, ¹Protalex Inc., Summit, NJ, ²QPS Holdings LLC, Newark, DE, ³Division of Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…
Abstract Number: 1274 • 2013 ACR/ARHP Annual Meeting
Maternal Vitamin D, Fetal C-Reactive Protein and Brain Natriuretic Peptide Associate With The Development and Morbidity Of Cardiac Neonatal Lupus
Amit Saxena¹, Peter M. Izmirly², Joanne H. Reed³, Sara Sahl², Deborah Friedman⁴, Robert M. Clancy³ and Jill P. Buyon², ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Women with anti-Ro antibodies face the risk of having a child with cardiac Neonatal Lupus (NL), characterized by congenital heart block and/or cardiomyopathy. Biomarkers…
Abstract Number: 313 • 2013 ACR/ARHP Annual Meeting
The DC-STAMP⁺IL17A⁺ Cell Subset Is Elevated In Psoriatic Arthritis (PsA) Patients and Declines Following Anti-TNFi Therapy
Yahui Grace Chiu¹, Edward M. Schwarz², Hua He³, Francisco A. Tausk⁴, Sharon Moorehead⁵, Michelle Smith⁵ and Christopher T. Ritchlin⁵, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Biostatistics and Computational Biology, University of Rochester, Rochester, NY, ⁴Dermatology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop psoriatic arthritis (PsA), a potentially destructive joint disease, within 10 years of Ps onset. Although early diagnosis…
Abstract Number: 71 • 2013 ACR/ARHP Annual Meeting
Subchondral Bone Turnover and Osteophyte Formation Are Key Aspects In The Progression Of Osteoarthritis and May Be Assessed and Predicted By a-CTX
Morten Asser Karsdal¹, Janet L. Huebner², Virginia Byers Kraus², Diana J. Leeming¹, Edward Coleman², Gary E. McDaniel³, Kim M. Huffman³, Kim Henriksen¹ and Anne C. Bay-jensen¹, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ³Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritic disease. It is characterized by pathological changes in both bone and cartilage turnover as well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].